International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationPredictive Factors for Acute and Late Urinary Toxicity After Permanent Prostate Brachytherapy: Long-Term Outcome in 712 Consecutive Patients
Introduction
Permanent low-dose-rate prostate brachytherapy (PB) is a standard option for the treatment of early-stage prostate cancer. PB is often chosen because of its excellent long-term disease control, convenience, and relative absence of severe long-term side effects 1, 2, 3. Additional research into brachytherapy-related toxicity and measures to reduce side effects and preserve patients' quality of life are essential.
Irritative and obstructive urinary symptoms are the main sequelae of PB 4, 5. Acute urinary retention (AUR) is a frequent acute urinary toxicity with published rates of 6–36% (5). Although many publications have described urinary toxicity after PB, few reports have included a large number of patients (>300) 3, 4, 6, 7, 8, described a systematic analysis of treatment and dosimetry predictive factors 4, 7, 8, 9, 10, 11, 12, or have had long-term follow-up 4, 6, 7, 8.
We describe the frequency of acute and late urinary toxicity and associated predictive factors for Radiation Therapy Oncology Group (RTOG) toxicity, International Prostate Symptom Score (IPSS) resolution, and changes in urinary bother score in 712 consecutive PB patients with a median follow-up of 57 months. The incidence and predictive factors for AUR in this cohort have been previously published by our group (5).
Section snippets
Methods and Materials
The Prostate Brachytherapy Program at the British Columbia Cancer Agency was established in 1997. As of March 2008, >2,200 patients had undergone PB. The outcome analysis of the first 1,006 consecutive patients revealed a 5-year Kaplan-Meier freedom from biochemical failure rate of 95.7% 13, 14. The program maintains a large prospective database containing baseline clinical and dosimetric data, follow-up prostate-specific antigen (PSA) level, and testosterone level. Toxicity data were collected
Results
A total of 712 patients (76.4% of all implanted patients) with ≥34 months of follow-up were included in this analysis. The median follow-up was 57.1 months (range, 34–103.9). The demographics are listed in Table 1.
Discussion
To our knowledge, this is the second largest single-institution report of long-term urinary toxicity after PB (7) and the largest study reporting the predictive factors for urinary toxicity. Our group had previously published a detailed analysis of AUR and its predictive factors in the same group of patients; therefore, the AUR analysis was not repeated for the purposes of the present study. In our previous work, we found that AUR rates had dramatically decreased in our program. The AUR rate in
Conclusion
The results of our study have shown that long-term urinary toxicity after PB is very low. In most patients, the IPSS normalized within 12–18 months after implantation. A greater prostate dose, greater maximal postimplant IPSS, and AUR slowed the IPSS resolution time. Patients with a larger prostate volume, a larger number of needles used, a greater baseline IPSS, and given HT had more acute toxicity. Patients with late RTOG Grade 2 or greater toxicity had a greater baseline IPSS, greater
Acknowledgments
BC Cancer Agency Prostate Brachytherapy Program: Drs. Mira Keyes (program head), W. James Morris (quality assurance chair), Michael McKenzie, Alexander Agranovich, Tom Pickles, Eric Berthelet, Howard Pai, Winkle Kwan, Mitchell Liu, Jonn Wu, Ross Halperin; medical physics: Ingrid Spadinger (physics head), Robert Harrison, William Kwa, Vincent Lapointe; data analyst: Barb Baerg; statistician: Veronika Morvan.
References (34)
- et al.
10-Year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy
Int J Radiat Oncol Biol Phys
(2001) - et al.
12-Year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer
J Urol
(2005) - et al.
Five-year outcome of intraoperative conformal permanent I-125 interstitial implantation for patients with clinically localized prostate cancer
Int J Radiat Oncol Biol Phys
(2007) - et al.
Urinary morbidity following ultrasound-guided transperineal prostate seed implantation
Int J Radiat Oncol Biol Phys
(1999) - et al.
Decline in urinary retention incidence in 805 patients after prostate brachytherapy: The effect of learning curve?
Int J Radiat Oncol Biol Phys
(2006) - et al.
Long-term urinary, sexual, and rectal morbidity in patients treated with iodine-125 prostate brachytherapy followed up for a minimum of 5 years
Urology
(2007) - et al.
The influence of isotope and prostate volume on urinary morbidity after prostate brachytherapy
Int J Radiat Oncol Biol Phys
(2006) - et al.
Long-term urinary sequelae following 125Iodine prostate brachytherapy
J Urol
(2008) - et al.
Urinary morbidity with a modified peripheral loading technique of transperineal 125I prostate implantation
Int J Radiat Oncol Biol Phys
(2000) - et al.
Temporal resolution of urinary morbidity following prostate brachytherapy
Int J Radiat Oncol Biol Phys
(2000)
Toxicity and early biochemical outcomes from 125Iodine prostate brachytherapy in the UK: A prospective study
Clin Oncol (R Coll Radiol)
Prediction of urinary symptoms after 125iodine prostate brachytherapy
Clin Oncol (R Coll Radiol)
Brachytherapy for carcinoma of the prostate: Techniques, patient selection, and clinical outcomes
Semin Radiat Oncol
for the Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia
J Urol
Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: Analysis of RTOG studies 7506 and 7706
Int J Radiat Oncol Biol Phys
Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen before prostate brachytherapy
Urology
Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy
J Urol
Cited by (0)
Presented at the ESTRO Leipzig, September 2006 and ABS Chicago, May 2007.
Conflict of interest: none.